What ICD-10 code should be used for a thyroid ultrasound finding of a 3.8 x 2.2 x 2.5 cm solitary thyroid nodule with TI-RADS (Thyroid Imaging Reporting and Data System) 3 classification?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD-10 Code for Thyroid Nodule with TI-RADS 3 Classification

The appropriate ICD-10 code for a 3.8 x 2.2 x 2.5 cm solitary thyroid nodule with TI-RADS 3 classification is D34 (Benign neoplasm of thyroid gland).

Rationale for Code Selection

The selection of D34 is based on several key factors from the ultrasound findings:

  1. TI-RADS Classification: The nodule is classified as TI-RADS 3, which according to the American College of Radiology (ACR) TI-RADS risk stratification system indicates a low to intermediate risk of malignancy (2-10%) 1. This classification suggests a predominantly benign nature of the nodule.

  2. Nodule Characteristics: The report describes a "mixed cystic solid hypoechoic nodule," which is consistent with TI-RADS 3 features that typically include mixed composition and some solid components 1.

  3. Size Consideration: While the nodule is large (3.8 x 2.2 x 2.5 cm) and meets criteria for fine needle aspiration (FNA), size alone does not indicate malignancy. The TI-RADS 3 classification takes precedence in determining the appropriate coding.

Alternative Codes to Consider

  • E04.1 (Nontoxic single thyroid nodule) - This could be considered but is less specific than D34 for a nodule that has been characterized by imaging.
  • D44.0 (Neoplasm of uncertain behavior of thyroid gland) - This would be more appropriate if the TI-RADS classification was 4 or 5, indicating higher suspicion for malignancy.

Clinical Implications

The TI-RADS 3 classification indicates a low to intermediate risk of malignancy (2-10%) 1, 2. Research shows that nodules in this category rarely turn out to be malignant upon cytological examination 2. In a study of 361 thyroid nodules with ACR TI-RADS reports, no TR3 nodules were associated with Bethesda category V or VI diagnoses (suspicious for malignancy or malignant) 2.

Management Considerations

While the ICD-10 code D34 reflects the likely benign nature of this nodule, it's important to note that:

  1. The radiologist has recommended fine needle aspiration (FNA) due to the nodule's size (3.8 x 2.2 x 2.5 cm), which exceeds the size threshold for FNA in TI-RADS 3 nodules.

  2. According to ACR guidelines, TI-RADS 3 nodules ≥1.5 cm should undergo FNA or follow-up ultrasound examination 3.

  3. The definitive diagnosis will be established after FNA cytology, which may necessitate updating the ICD-10 code based on those results.

Coding Pitfalls to Avoid

  1. Don't code as malignant (C73) without cytological or histological confirmation, even if FNA is recommended.

  2. Don't use R codes (symptoms and signs) such as R59.0 (Localized enlarged lymph nodes) as these are less specific than D34 when imaging has characterized the nodule.

  3. Don't use E04.2 (Nontoxic multinodular goiter) as the report specifically mentions a solitary nodule.

The code D34 most accurately reflects the current clinical understanding of this nodule based on its TI-RADS 3 classification, while acknowledging that further evaluation with FNA is warranted due to its size.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.